ACP-204 + Placebo
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lewy Body Dementia Psychosis
Conditions
Lewy Body Dementia Psychosis
Trial Timeline
Aug 6, 2025 → Mar 1, 2028
NCT ID
NCT07029581About ACP-204 + Placebo
ACP-204 + Placebo is a phase 2 stage product being developed by Acadia Pharmaceuticals for Lewy Body Dementia Psychosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07029581. Target conditions include Lewy Body Dementia Psychosis.
What happened to similar drugs?
1 of 3 similar drugs in Lewy Body Dementia Psychosis were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07029581 | Phase 2 | Recruiting |
| NCT06159673 | Phase 2/3 | Recruiting |
Competing Products
13 competing products in Lewy Body Dementia Psychosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2020 + Placebo | Eisai | Approved | 43 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 26 |
| Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo | Eisai | Phase 3 | 40 |
| 3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo | Eisai | Phase 2 | 35 |
| E2027 | Eisai | Phase 2 | 35 |
| Irsenontrine + Placebo | Eisai | Phase 2 | 35 |
| E2020 | Eisai | Phase 2 | 35 |
| E2027 | Eisai | Phase 1 | 29 |
| LY3154207 + Placebo | Eli Lilly | Phase 2 | 35 |
| HTL0018318 + Placebo | Nxera Pharma | Phase 2 | 27 |
| ACP-204 | Acadia Pharmaceuticals | Phase 3 | 44 |
| Neflamapimod + Placebo | CervoMed | Phase 2 | 25 |
| neflamapimod | CervoMed | Phase 2 | 29 |